Home » Archive by Category


San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

The Genome Institute at Washington University Receives Irys System from BioNano Genomics to Advance Research for Genome Reference Consortium

October 14, 2014 – 5:00 am | Edit Post

SAN DIEGO and ST. LOUIS, Oct. 14, 2014 /PRNewswire/ — BioNano Genomics announced today the purchase of an Irys™ System by The Genome Institute at Washington University in St. Louis to assist, among other projects, in improving the quality of the human reference genome for the Genome Reference Consortium (GRC). The goal of the GRC is to ensure that the human, mouse and zebrafish reference assemblies are biologically relevant by closing gaps, fixing errors and representing complex variation. The team of researchers at The Genome Institute, led by Dr. Richard Wilson, will use the Irys System in their workflow as they determine the sequence, location and orientation of genes and transposable elements in the human genome.

The Genome Institute originated to play a key role in the Human Genome Project, an international effort to decode the human genetic blueprint, and ultimately contributed 25 percent of the finished sequence. Although the Human Genome Project was completed in 2003, research continues to not only finish sections of the sequence that contain gaps, missing information and misaligned or misrepresented regions but also to understand how genomic variations account for diversity and disease. 

“We are focused on many of the issues associated with sequencing human genomes, which include resolving complex repetitive or highly variable regions, improperly assembled areas, and regions for which no sequence exists in the current reference resource,” said Richard K. Wilson, Ph.D., Director of The Genome Institute and Professor of Genetics at Washington University in St. Louis. “We will use BioNano’s Irys System to produce high-quality human genome sequences and better understand regions of the genome that are associated with human disease.”

The GRC was created to improve the sequence quality and accuracy of the human assembly as well as improve the reference genomes of other model organisms, including the mouse and zebrafish, which are often used as models for human disease. The members of the Genome Reference Consortium are The Genome Institute at Washington University, National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EBI), and Wellcome Trust Sanger Institute. 

“The Irys System will be used to order and orient the sequences from next-generation sequencing technologies as well as penetrate difficult repeat regions to inform genome assembly, annotation, and structural variation analysis,” said Bob Fulton, Director of Project Development and Management at The Genome Institute. “With a clearer knowledge of structural variations we can begin to accurately assemble the human genome and use that information to discover biologically significant patterns in structural variations that are relevant to genetic diversity and human diseases.”

Genome maps built with the Irys System reveal the biologically and clinically significant order and orientation of functionally relevant components of complex genomes, including genes, promoters, regulatory elements as well as the length and location of long areas of repeats across the entire genome. Assembling such a comprehensive view of a genome has previously been a major hurdle for genomics researchers because information about repetitive elements and structural variations are lost with next generation sequencing methods.

“We are excited to help The Genome Institute in their mission to make the best possible human reference available to scientists around the world,” said Todd Dickinson, Ph.D., vice president, Global Commercial Operations of BioNano Genomics. “Comprehensive detection of all genome variation will lead to a better understanding of human health and disease and will be essential to advance genomic research into the clinic.”

About Irys System

Irys makes it possible to routinely and accurately detect genomic structural variation and to finish genome assemblies. The fully automated Irys benchtop instrument uses the IrysChip to uncoil and confine long DNA molecules in proprietary Nanochannel Arrays™ where they are uniformly linearized in a highly parallel display for high-resolution, single-molecule imaging. Irys does not employ DNA fragmentation or amplification, which are typical with next-generation sequencing. The result is sequence information over extremely long “reads” ranging from hundreds of kilobases to a megabase, where the sample’s valuable structural information is preserved. Irys makes it possible for researchers to directly observe structural variants including replications, deletions, translocations and inversions.

About BioNano Genomics

Headquartered in San Diego, BioNano Genomics is delivering an altogether better way of gaining a fully informed understanding of genomes. The Company’s platform provides researchers and clinicians the most comprehensive, organized and actionable picture of a genome with unprecedented insights into how the individual components of genomes are ordered, arranged, and interact with each other. BioNano Genomics works with institutions in life science, translational research, molecular diagnostics and personalized medicine. The Company is supported by private investors and grant funding from genomics programs at federal agencies, including the NIH and NIST-ATP.


Notes: BioNano Genomics is a trademark of BioNano Genomics, Inc. Any other names of actual companies, organizations, entities, products or services may be the trademarks of their respective owners.
SOURCE BioNano Genomics

Aethlon Medical Announces First Treatment Of An Ebola Patient

October 14, 2014 – 5:00 am | Edit Post

Aethlon Medical Announces First Treatment of an Ebola PatientSAN DIEGO, Oct. 14, 2014 /PRNewswire/ — Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), announced today the first use of Hemopurifier therapy on a patient infected with Ebola virus. The treatment was administered to…

Cypher Genomics Forms Scientific Advisory Board to Advance Genome Interpretation and Biomarker Discovery Services

October 14, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 14, 2014 /PRNewswire/ – Cypher Genomics, Inc., the genome informatics company, announced today the formation of a scientific advisory board (SAB) to guide the development and implementation of Cypher’s products, which include MantisTM, the genome interpretation software as a service offering, and CoralTM, a biomarker discovery service. Drs. Kelly Bethel, Michael Hultner, Myla Lai-Goldman, Arnold (Arnie) Levine and Diego Miralles have joined as members of the SAB, alongside Dr. Nicholas Schork, who co-founded Cypher Genomics and is the SAB’s chair. Designed for pharmaceutical companies, clinical laboratories and to support population genomics efforts, Cypher’s fast, accurate and robust genome interpretation and analysis technologies facilitate differentiated molecular tests, efficient clinical trials and enable precision therapeutic decisions. 

“Cypher has gathered an exceptional team of scientific advisors who each bring distinctive skill sets to the board. Drs. Bethel and Lai-Goldman are physicians that have routinely utilized genomic information in their medical practices and at leading diagnostic companies, respectively. Dr. Hultner innovates at the interface of technology and healthcare with a focus on population genomics and Dr. Miralles focuses on emerging technologies with applicability to pharmaceutical companies,” said Ali Torkamani, PhD., the company’s co-founder and chief scientific officer. “With his co-discovery of the p53 tumor suppressor gene, Dr. Levine is renowned as a pioneer in cancer research and genomics. We look forward to working with these thought leaders to advance Cypher’s genome interpretation technology to find clinically meaningful information in human sequencing data to improve healthcare.”

“The identification and confirmation of a gene that is associated or linked to a disease requires a diverse and experienced team and previously necessitated years and even decades of research,” said Levine. “I look forward to working with Drs. Bethel, Hultner, Lai-Goldman, Miralles and Schork to advance Cypher’s technology for the discovery of the genetic basis of complex diseases and traits, to better diagnose patients, understand drug response and, ultimately, deliver on personalized medicine.”

Kelly Bethel, M.D., is a practicing hematopathologist in the Scripps Clinic Medical Group and holds an adjunct appointment at The Scripps Research Institute. In addition to her clinical practice, she is the medical director of the Blood Bank at Scripps Clinic and Green Hospital, the past program director of the Scripps Hematopathology Fellowship, and participates in various translational research activities investigating circulating tumor cells, anemia, low-grade B-cell malignancies and myelodysplasia. She completed an internship in pediatrics, a residency in anatomic and clinical pathology, and subspecialty training in hematopathology at the Naval Medical Center San Diego. She received her B.A. in English literature from Yale University and her M.D. from George Washington University School of Medicine and Health Sciences. Dr. Bethel is board certified in anatomic and clinical pathology and hematopathology.

Michael Hultner, Ph.D. is chief scientist for Lockheed Martin’s Health and Life Sciences (HLS) division where he promotes technical and business innovations to position HLS for future new business in healthcare IT. He currently manages a diverse portfolio of healthcare innovations including big data analytics, population-scale genomics, and synthetic biology. As a Lockheed Martin Fellow, Dr. Hultner supports corporate engineering and technology with subject matter expertise, strategy, and business development in advanced information fusion, machine learning, software development, and program management. Dr. Hultner received his Ph.D. in biomedical sciences from the University of California, San Francisco and an undergraduate degree in molecular biology from University of California, San Diego.

Myla Lai-Goldman, M.D. is the chief executive officer and a founder of GeneCentric Diagnostics. Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America Holdings (LabCorp), with the last 10 years as executive vice president, chief medical officer and chief scientific officer. During her tenure at LabCorp, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. After leaving LabCorp, she became a venture partner at Hatteras Venture Partners. Dr. Lai-Goldman received her M.D. from Columbia University College of Physicians and Surgeons and is board certified in anatomic and clinical pathology.

Arnold Levine, Ph.D. is a pioneering cancer research scientist, having discovered the p53 tumor suppressor protein in 1979. He established the Simons Center for Systems Biology at the Institute for Advanced Study, which concentrates on research at the interface of molecular biology and the physical sciences in cancer biology. Dr. Levine was previously president of The Rockefeller University, and prior to that he was the Harry C. Wiess Professor in Life Sciences and former chairman of the Department of Molecular Biology at Princeton University. He is a member of the National Academy of Sciences and serves on a number of cancer center scientific advisory boards. Dr. Levine holds a Ph.D. in microbiology from the University of Pennsylvania and a B.A. from Harpur College, State University of New York at Binghamton.

Diego Miralles, M.D. is Global Head of Innovation, Janssen and leads a multi-disciplinary group focused on enhancing the value of the pharmaceutical business by identifying and integrating emerging technologies and novel partnerships in areas including genomics and clinical trials. In addition, Dr. Miralles is the management sponsor of Janssen Labs and site head of the Janssen West Coast Research Center, part of Janssen Research & Development LLC where he oversees the business and operational management of Janssen Labs including the initial concept development, site construction, business model architecting and company selection criteria. He graduated from the University of Buenos Aires and completed his residency in internal medicine at the Mayo Clinic in Rochester, Minn. followed by a fellowship in infectious diseases at Cornell University and New York Hospital. 

Nicholas Schork, Ph.D. is a co-founder of Cypher Genomics and chair of Cypher’s SAB. Dr. Schork is a world-expert in quantitative and integrated human genetics and genomics, particularly the design and implementation of methodologies to dissect the genetic basis of complex traits and diseases and is the lead inventor of Cypher Genomics’ biomarker discovery technology. He is professor and director of Human Biology at the J. Craig Venter Institute and the head of Integrated Genomics at Human Longevity, Inc. Dr. Schork has published more than 425 scientific articles and book chapters on the analysis of complex, multifactorial traits and diseases. 

About Cypher Genomics

Cypher Genomics is a leading genome informatics company offering a highly accurate, rapid and robust interpretation software solution for users of human genome sequencing. The proprietary, automated genomic interpretation platform allows clinical laboratories to tune Cypher Genomics’ market leading sensitivity and specificity profiles to develop molecular tests for diagnostic and prognostic use and pharmaceutical companies to discover biomarkers from whole genome sequence data in sample sizes typical of early stage drug development studies. Through MantisTM, the genome interpretation software as a service offering, and CoralTM, a biomarker discovery service, Cypher Genomics can improve health care and reduce costs by facilitating improved diagnostic accuracy and earlier interventions, optimizing therapeutic approaches and reducing adverse drug reactions. Cypher Genomics is located in San Diego, California.

For more information about Cypher Genomics, visit www.cyphergenomics.com and follow us on Twitter @cyphergenomics.
SOURCE Cypher Genomics, Inc.

Targeted Medical Pharma Releases Promising Trial Results For The Treatment Of Posttraumatic Stress Disorder

October 14, 2014 – 5:00 am | Edit Post

Study Shows Medical Foods Sentra AM and Sentra PM Effective at Reducing Symptoms of PTSD in VeteransLOS ANGELES–(BUSINESS WIRE)–Targeted Medical Pharma, Inc. (TRGM), a drug discovery and development company, today announced the results of a clinical trial studying the amino acid based medical foods, Sentra AM and Sentra PM in Veterans suffering from symptoms associated…

John Wayne Cancer Institute Auxiliary To Honor And At Oct. 23

October 14, 2014 – 5:00 am | Edit Post

SANTA MONICA,Calif., Oct. 14, 2014 /PRNewswire/ –The John Wayne Cancer Institute Auxiliary (JWCIA) will honor Marilou Terpenning, MD, John Wayne Cancer Institute oncologist, with the Angel Award; and Dan Hay, president and CEO of Premier Girls Fastpitch and Surf City Tourneys…

Quidel Corporation Receives FDA Clearance For Its Lyra(R) Molecular PCR Assay For The Detection Of Adenovirus

October 14, 2014 – 5:00 am | Edit Post

Quidel Receives FDA Clearance for Its Lyra(R) Molecular PCR Assay for the Detection of AdenovirusSAN DIEGO, CA–(Marketwired – Oct 13, 2014) – Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United…

Cypher Genomics Forms Scientific Advisory Board To Advance Genome Interpretation And Biomarker Discovery Services

October 14, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 14, 2014 /PRNewswire/ –Cypher Genomics, Inc., the genome informatics company, announced today the formation of a scientific advisory board (SAB) to guide the development and implementation of Cypher’s products…

DNAtrix, Inc. Completes $20 Million Series B Financing

October 14, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 14, 2014 /PRNewswire/ — DNAtrix, a clinical-stage oncolytic immunotherapy company, announced that it has completed a $20M Series B equity financing. New investor Morningside Ventures led the round and was joined by existing investors including Mercury Fund, Targeted…

Venture Firms Turn Down Funding Volume, but Still Rockin’ in Q3

October 14, 2014 – 4:00 am | Edit Post

Venture capital activity descended from the stratosphere during the third quarter, but it was still flying high, as venture firms invested nearly $9.8 billion in 879 deals across the United States,…

[[Click headline to continue reading.]]

Untying the Knots in Big Data and Big Biology: Q&A with Andrew Su

October 13, 2014 – 11:15 am | Edit Post

As big data becomes increasingly important in using genomic information, the National Institutes of Health is funding a sweeping initiative to help untie the knots that make it hard to extract and…

[[Click headline to continue reading.]]